NeuroMab™ Anti-Tau; pTau BBB Shuttle Antibody(NRZP-1022-ZP3101)

Figure 1 shows the characterization of the specificity of the tau antibody by immunoblot analysis of total brain lysates from nTg, tau KO, and PS19 tau Tg mice using actin as a control.

Figure 2 shows the specificity of tai antibodies raised against the tau peptide p193-211, as determined by immunoblotting with recombinant tau protein phosphorylated in vitro by p42 MAPK or GSK3β.

Figure 3 shows immunocytochemistry of representative tau pathology in human AD brain and JNPL3 Tg mice with antibodies 2D1 and 7F2.

Immuno-reactivity of previously characterized phospho-tau antibodies AT8 and new tau antibodies 2D1 or 7F2 in the hippocampus of a control subject or a subject with AD, and in the spinal cord of 12 month old nTg and JNPL3 Tg mice. Arrows indicating NFTs in human brain or NFT-like inclusion pathology in JNPL3 mice. Asterisks depict dystrophic neurites within senile plaques. Bar=100 μm, and 200 μm for insets.

Figure 4 shows the biochemical characterization of sarcosyl-insoluble tau detected by a tau antibody in human brain lysates from AD patients.